SCHEMBL5456549

SCHEMBL5456549

Clc1ccc2[nH]c3c(c2c1)CCCC3NC1CCCCC1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.70
SMN1; SMN2 Q16637 3/20 0.70
MAPT P10636 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
GLA P06280 1/20 0.70
RB1 P06400 6/20 0.69
MAPK1 P28482 1/20 0.64
SIRT1 Q96EB6 7/20 0.56
DHODH Q02127 1/20 0.55
SIRT2 Q8IXJ6 3/20 0.55
SIRT3 Q9NTG7 2/20 0.55
HTR2A P28223 2/20 0.55
HTR2C P28335 2/20 0.55
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456640 0.85 RB1 (0.69) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4163723 0.85 RB1 (0.69) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5394699 0.85 RB1 (0.69) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL14361410 0.85 RB1 (0.69) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL21998619 0.84 RB1 (0.68) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL16433477 0.83 ALOX15 (0.71) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5456637 0.82 RB1 (0.72) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL15265267 0.82 MAPT (0.57) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL4196380 0.82 RB1 (1.00) ALOX15SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL5458538 0.81 RB1 (0.63) ALOX15SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
EP-1678137-A1 COMPOSITIONS AND METHODS FOR VIRAL INHIBITION CHIRON CORPORATION (US) 2006-07-12 EP disclosed
WO-2005037791-A1 COMPOSITIONS AND METHODS FOR VIRAL INHIBITION CHIRON CORPORATION (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 ALOX15 655/4885SMN1; SMN2 4824/4885MAPT 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.